L26/P-914 Does intraovarian combination therapy with exosomes and platelet-rich plasma (PRP) improve IVF outcomes in women with Diminished Ovarian Reserve?
Human Reproduction · 01.07.2026 · 41 (Supplement_1)
DOI: 10.1093/humrep/deag083.1238 ↗Kurz gefasst
Fachartikel in der Zeitschrift Human Reproduction, online erschienen am 08.07.2026. Verfasst von S. Kilinc und 2 weiteren Autor:innen.
Abstract (Originalsprache)
Study question Does intraovarian combination therapy with exosomes and platelet-rich plasma (PRP) improve IVF outcomes in women with Diminished Ovarian Reserve? Summary answer Exosome–PRP therapy enhances oocyte maturity and fertilization without increasing oocyte numbers, suggesting quality optimization, with benefit in women aged 35–45 years and low MII counts. What is known already Diminished ovarian reserve, particularly with advancing age, is a major contributor to IVF failure. PRP has been explored as a regenerative intervention, and exosomes are key mediators of intercellular signaling and tissue repair. However, clinical evidence supporting the combined use of exosomes and PRP in assisted reproduction is limited. Study design, size, duration This was a retrospective observational study including approximately 180 women undergoing IVF following exosome-based (plasma and urine exosome) ovarian therapy. Exosomes were isolated from patients’ own biological materials using an ultrafiltration method. Subgroup analyses were performed according to age, menstrual cycle regularity, gene expression (WNT1, WNT3A, WNT5A and mtDNA), tissue factor levels and treatment modality (PRP + exosome or PRP + exosome + MSC). Participants/materials, setting, methods Women undergoing IVF treatment received intraovarian exosome therapy combined with PRP, with or without mesenchymal stem cell supplementation. Pre- and post-procedural parameters (total oocyte count, MII oocyte count, pronuclear formation, gene expression levels, tissue factor levels) and pregnancy outcomes were assessed. Plasma- and urine-derived exosomes were analyzed for particle size distribution and tissue factor levels in relation to age and menstrual cycle regularity. Main results and the role of chance Overall pregnancy rate was 10.66%. Among pregnancy-positive cases, 2.66% were spontaneous pregnancies, 1.33% biochemical pregnancies, and 1.33% clinical pregnancies. Baseline oocyte, MII oocyte, and PN counts did not differ significantly between women with regular and irregular menstrual cycles (p > 0.05). Post-intervention, the proportion of mature oocytes and fertilization-related outcomes increased significantly, particularly in women with irregular cycles (p < 0.05). No statistically significant difference in pregnancy outcomes was observed between PRP + exosome + MSC and PRP + exosome groups (p > 0.05). Pregnancy rates were lowest in women <35 years, higher in those aged 35–40 and 40–45 years, and absent in women >45 years. Analysis revealed that WNT1, WNT3A, WNT5A, and mtDNA gene expression did not differ significantly between the subgroups (p > 0.05). Plasma tissue factor levels differed significantly across age groups (one-way ANOVA, p = 0.040). Plasma-derived exosomes showed significant age- and menstrual cycle–related differences in particle size and tissue factor levels (p < 0.05), whereas urine-derived exosomes showed no significant variation (p > 0.05). Total oocyte counts were preserved or slightly reduced after treatment (p > 0.05), while the proportion of mature oocytes and fertilization-related outcomes improved significantly (p < 0.05). Limitations, reasons for caution The retrospective design, lack of a randomized control group, and limited subgroup sizes restrict causal inference. Treatment heterogeneity and low absolute pregnancy rates limit generalizability. Biomarker analyses were exploratory and require validation. Wider implications of the findings Exosome–PRP therapy may be a novel adjunct for diminished ovarian reserves by improving oocyte competence rather than yield. These findings support randomized trials and indicate plasma-derived exosomes are more sensitive to patient-specific parameters, serving as useful biomarkers of ovarian response and treatment efficacy, while urinary exosomes remain stable overall clinically Trial registration number Yes
Zitieren
APA
Kilinc, S., Tiras, B., & Memo, E. (2026). L26/P-914 Does intraovarian combination therapy with exosomes and platelet-rich plasma (PRP) improve IVF outcomes in women with Diminished Ovarian Reserve?. Human Reproduction, 41(Supplement_1). https://doi.org/10.1093/humrep/deag083.1238
Vancouver
Kilinc S, Tiras B, Memo E. L26/P-914 Does intraovarian combination therapy with exosomes and platelet-rich plasma (PRP) improve IVF outcomes in women with Diminished Ovarian Reserve?. Human Reproduction. 2026;41(Supplement_1). doi:10.1093/humrep/deag083.1238
BibTeX
@article{Kilinc2026,
author = {Kilinc, S. and Tiras, B. and Memo, E.},
title = {L26/P-914 Does intraovarian combination therapy with exosomes and platelet-rich plasma (PRP) improve IVF outcomes in women with Diminished Ovarian Reserve?},
journal = {Human Reproduction},
year = {2026},
volume = {41},
number = {Supplement_1},
doi = {10.1093/humrep/deag083.1238}
}
EUVIMED